SCHEMBL1965012

SCHEMBL1965012

CCOC1(CC)Oc2ccccc2O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 10/20 0.36
MAPT P10636 7/20 0.36
KDM4E B2RXH2 5/20 0.36
APEX1 P27695 2/20 0.36
GAA P10253 7/20 0.35
RECQL P46063 4/20 0.35
TDP1 Q9NUW8 4/20 0.35
LMNA P02545 3/20 0.35
POLB P06746 3/20 0.35
HSD17B10 Q99714 3/20 0.35
ALOX12 P18054 2/20 0.35
HPGD P15428 1/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
ALOX15 P16050 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GLA P06280 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963746 0.84 SMN1; SMN2 (0.35) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1
SCHEMBL11506768 0.78 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1
SCHEMBL1964236 0.77 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1
SCHEMBL29838901 0.77 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1
SCHEMBL11843309 0.70 ALDH1A1 (0.34) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1
SCHEMBL9428200 0.69 MAPT (0.35) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1
SCHEMBL27601726 0.66
SCHEMBL15732860 0.65 SMN1; SMN2 (0.39) SMN1; SMN2POLBMEN1KMT2A
SCHEMBL11629078 0.63 ALDH1A1 (0.35) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1
SCHEMBL31633760 0.63 SIGMAR1 (0.40) SMN1; SMN2ALDH1A1MAPTKDM4EAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513028-B1 METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, USE OF SAID ALIZARIN COMPOUND, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR FUJIFILM CORP (JP) 2018-06-20 EP disclosed
US-8741513-B2 Method for preparing alizarin derivative compound, novel alizarin derivative compound, surface modification method, photoelectric conversion film, photoelectric conversion element, and electrophotographic photoreceptor FUJIFILM CORPORATION (JP) 2014-06-03 US disclosed
EP-2513028-A1 METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR FUJIFILM Corporation (JP) 2012-10-24 EP disclosed
US-20120244462-A1 METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR FUJIFILM CORPORATION (JP) 2012-09-27 US disclosed
WO-2011071130-A1 METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR FUJIFILM CORPORATION (JP) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120244462-A1 METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR NR2E3, INA, NHERF1 SMN1; SMN2 2818/4885ALDH1A1 783/4885MAPT 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.